{"classes":[{"categories":[{"measurements":[{"comment":"Has not been reached","groupId":"OG000","lowerLimit":"24.5","upperLimit":"NA","value":"31.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"58"}],"units":"Participants"}],"description":"Progression-free survival after CVDD in participants with newly diagnosed active multiple myeloma. PFS: time from the initiation of therapy to progression, relapse or death from any causes.\n\nProgressive Disease (PD): Progressive Disease requires any one or more of the following:\n\nIncrease of ≥ 25% from baseline in:\n\n* serum M-component and /or (the absolute increase must be ≥ 0.5 g/dL)\n* urine M-component and/or (the absolute increase must be ≥ 200 mg/24 h)","dispersionType":"95% Confidence Interval","groups":[{"description":"Arm A:\n\n* Dose Level 1: Cyclophosphamide 250 mg /m\\^2 IV Day 1; VELCADE, 1.0 mg/m\\^2 IV days 1,4,8, and 11; DOXIL 30 mg/m\\^2 Day 4; Dexamethasone 20 mg orally daily on days 1-2,4-5,8-9,11-12\n* Dose Level 2: Cyclophosphamide 500 mg /m\\^2 IV Day 1; VELCADE, 1.0 mg/m\\^2 IV days 1,4,8, and 11; DOXIL 30 mg/m\\^2 Day 4; Dexamethasone 20 mg orally daily on days 1-2,4-5,8-9,11-12\n* Dose Level 3: Cyclophosphamide 750 mg /m\\^2 IV Day 1; VELCADE, 1.0 mg/m\\^2 IV days 1,4,8, and 11; DOXIL 30 mg/m\\^2 Day 4; Dexamethasone 20 mg orally daily on days 1-2,4-5,8-9,11-12\n* Dose Level 4: Cyclophosphamide 750 mg /m\\^2 IV Day 1; VELCADE, 1.3 mg/m\\^2 IV days 1,4,8, and 11; DOXIL 30 mg/m\\^2 Day 4; Dexamethasone 20 mg orally daily on days 1-2,4-5,8-9,11-12\n\nArm B:\n\nParticipants received Cyclophosphamide and VELCADE at Level 4 (the MPD) at the same schedule of the Phase I study. Pegylated doxorubicin and Dexamethasone were given at the same doses and schedule as the Phase I part of study.","id":"OG000","title":"All Participants"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"Up to 50.9 months","title":"Phase II: Progression-Free Survival (PFS)","type":"SECONDARY","unitOfMeasure":"months"}